PASADENA, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, today announced the passing of its founder and Executive Chairman, John S. Kovach, M.D. Dr.…Read More
LIXTE Biotechnology Holdings Announces the Passing of its Founder John S Kovach
